Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer：

NCT05736952 is registered in ClinicalTrials.gov with Xinhua Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT05736952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05736952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer：
Lead sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Phase 2
Overall status
Withdrawn
Start date
March 1, 2023
Completion date
February 1, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant ovarian cancer